Completed PHASE4 INTERVENTIONAL 2-arm NCT01127360

LUCAS (Lucentis Compared to Avastin Study) (LUCAS)

LUCAS. A Randomized, Prospective, Multicenter Study Comparing the Effect of Intravitreal Injection of Bevacizumab to Ranibizumab When Given to Patients With Neovascular Age-related Macular Degeneration

Sponsor: Oslo University Hospital

Conditions Exudative Age-related Macular Degeneration

Interventions Bevacizumab Ranibizumab

Updated 5 times since 2017 Last updated: Jan 15, 2015 Started: Mar 31, 2009 Primary completion: Aug 31, 2014 Completion: Aug 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01127360, this PHASE4 trial focuses on Exudative Age-related Macular Degeneration and remains completed. Sponsored by Oslo University Hospital, it has been updated 5 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Oslo University Hospital

Data source: Oslo University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Oslo, Norway